Researchers Develop Experimental Vaccine Against Fungal Infections
Hold on a second, The Last of Us fans. Scientists have made strides in creating a new vaccine that might combat various types of fungal infections, including the ones that lead to vaginal yeast infections.
The University of Georgia’s research team has come up with a vaccine candidate named NXT-2. In their latest experiments with mice, NXT-2 seemed to shield the animals from a frequent cause of yeast infections, Candida albicans. The researchers are now eager to move into human trials.
Fungi, unlike bacteria or viruses, don’t tend to make folks sick all that often. However, there are definitely some common fungal ailments that can be quite uncomfortable, like yeast infections and ringworm. More seriously, fungi can pose severe health risks to individuals with weakened immune systems. Recently, the frequency of fungal infections appears to be rising—potentially influenced by climate change. Fungi typically thrive in cooler environments, so some species might be adapting to survive better in warmer conditions.
Another issue elevating the threat from fungi is the limited arsenal available against them. There are significantly fewer antifungals compared to antibiotics, and as of now, no approved vaccines exist. While new antifungal medications are necessary, they serve primarily as temporary measures since fungi can develop resistance over time. So, the researchers at UGA are hopeful that their “pan-fungal” vaccine could offer a more durable solution for dealing with the concerning fungal strains.
Previously, the NXT-2 vaccine showed promise in animal studies by effectively preventing or lessening damage from three of the main sources of invasive fungal infections, accounting for around 80% of fatal cases. The most recent research, published this month in NPJ Vaccines, specifically tested NXT-2 in a mouse model of vulvovaginal candidiasis.
The findings revealed that NXT-2 triggered a robust immune response in the mice against the C. albicans fungi, particularly in vaginal tissue. Mice that received the vaccine and then became infected displayed less fungal presence and also experienced reduced damage and inflammation in their vaginal tissue.
The research team noted, “These studies provide supportive evidence of the broad efficacy of NXT-2 and support the rationale for its further development as a single, pan-fungal vaccine for local and systemic fungal infections.”
While this vaccine might address the more serious fungal infections, the team plans to first test it in humans focused on recurrent vulvovaginal candidiasis (RVVC). This condition affects over 100 million women globally each year and can be incredibly distressing, particularly since younger, healthier women are more frequently impacted, making it easier to find volunteers for trials.
As lead author Karen Norris, a professor in immunology and translational biomedicine at UGA, mentioned, “RVVC is not life-threatening, but it is miserable. Up to one in 10 women experience this condition in their lifetime, suffering from three or more yeast infections annually. There’s a significant need for solutions.”
Norris also happens to be the CEO and founder of NXT Biologics, the biotech company working to advance NXT-2 commercially. If NXT-2 performs well against yeast infections, the focus will shift to tackling the more perilous fungal threats worldwide.
“I believe this vaccine could make the biggest impact on individuals who are at high risk for dangerous, life-threatening infections,” Norris added.
